Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04789057 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atorvastatin Effect on Reduction of COPD Exacerbations

Study acronym: Captain
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  2. Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Study completion date: Dec 31, 2025 to May 31, 2027
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2021 to Feb 11, 2022
    • Site details revised
    v3
  4. Start date: Mar 1, 2021 to Nov 1, 2021v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
It is a randomized, multicenter, prospective, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 12 Hospital Pulmonary Departments to evaluate the effectiveness of atorvastatin on the reduction of inflammation process in patients with chronic obstructive pulmonary diseases, and possible biomarkers for personalized treatment of COPD.
Trial Details
NCT Number NCT04789057
Lead Sponsor Medical University of Bialystok
Collaborators: Medical Research Agency, Poland
Conditions
(from sponsor)		 Copd, COPD Exacerbation, Smoking, Gene Expression, Atorvastatin
Related terms Pulmonary Disease, Chronic Obstructive, Smoking
Enrollment 460 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov